Akari Therapeutics (AKTX) Other Gross PP&E Adjustments (2011 - 2026)
Akari Therapeutics recorded quarterly Other Gross PP&E Adjustments of -$892000.0 in Q1 2026, down 9.58% quarter-over-quarter from -$814000.0 in Q4 2025, and up 42.49% year-over-year from -$626014.5 in Q1 2025.
Akari Therapeutics' Other Gross PP&E Adjustments history runs 16 years deep, the most recent figure standing at -$892000.0 for Q1 2026.
- In Q1 2026, Other Gross PP&E Adjustments rose 42.49% year-over-year to -$892000.0; the TTM figure through Mar 2026 stood at -$3.8 million (up 7.62% YoY), while the FY2025 annual figure was -$814000.0, up 37.62% from the prior year.
- Other Gross PP&E Adjustments came in at -$892000.0 for Q1 2026 at Akari Therapeutics, down from -$814000.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $85489.0 in Q1 2022 to a low of -$1.6 million in Q1 2025.
- A 5-year average of -$755463.2 and a median of -$814000.0 in 2025 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments sank 244.08% in 2025 and surged 42.49% in 2026, its largest moves.
- Akari Therapeutics' Other Gross PP&E Adjustments stood at -$955000.0 in 2022, then grew by 29.95% to -$669000.0 in 2023, then plunged by 95.07% to -$1.3 million in 2024, then jumped by 37.62% to -$814000.0 in 2025, then retreated by 9.58% to -$892000.0 in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$892000.0, -$814000.0, and -$814000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -75.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -892,000.00 |
| Mar 31, 2026 | -892,000.00 |
| Dec 31, 2025 | -1.06 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | -814,000.00 |
| Sep 30, 2025 | -814,000.00 |
| Jun 30, 2025 | -1.25 Mn |
| Jun 30, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | -861,000.00 |
| Sep 30, 2024 | -861,000.00 |
| Jun 30, 2024 | -363,000.00 |
| Jun 30, 2024 | -363,000.00 |
| Mar 31, 2024 | -519,000.00 |
| Mar 31, 2024 | -519,000.00 |
| Dec 31, 2023 | -669,000.00 |
| Dec 31, 2023 | -669,000.00 |
| Dec 31, 2022 | -955,000.00 |
| Dec 31, 2022 | -955,000.00 |
| Jun 30, 2022 | 85,489.00 |
| Jun 30, 2022 | 85,489.00 |
| Mar 31, 2022 | 85,489.00 |
| Mar 31, 2022 | 85,489.00 |
| Dec 31, 2021 | -1.43 Mn |
| Dec 31, 2021 | -1.43 Mn |
| Sep 30, 2021 | 85.49 Bn |
| Sep 30, 2021 | 85.49 Bn |
| Dec 31, 2020 | -1.13 Mn |
| Dec 31, 2020 | -1.13 Mn |
| Mar 31, 2020 | 85,489.00 |
| Mar 31, 2020 | 85,489.00 |
| Dec 31, 2019 | -1.24 Mn |
| Dec 31, 2019 | -1.24 Mn |
| Dec 31, 2018 | -1.59 Mn |
| Dec 31, 2018 | -1.59 Mn |
| Dec 31, 2017 | 56.00 |
| Dec 31, 2017 | 56.00 |
| Dec 31, 2016 | 58.00 |
| Dec 31, 2016 | 58.00 |
| Dec 31, 2015 | 41.00 |
| Dec 31, 2015 | 41.00 |
| Dec 31, 2014 | 67,000.00 |
| Dec 31, 2014 | 67,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Dec 31, 2012 | 13,000.00 |
| Dec 31, 2012 | 13,000.00 |
| Dec 31, 2011 | 9,000.00 |
| Dec 31, 2011 | 9,000.00 |